Verastem Executives Featured at Boston-Area Biotechnology Events

Verastem Executives Featured at Boston-Area Biotechnology Events

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Verastem, Inc. (NAS: VSTM) , focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that President/Chief Executive Officer, Robert Forrester, Chief Medical Officer, Dr. Joanna Horobin, and Head of Research, Dr. Jonathan Pachter, will participate in upcoming life science panel discussions later this month. The details of the events are below.

Women who Inspire
Date: Wednesday, October 16, 2013 (7:30 - 9:00 a.m.)
Location: Biogen Idec, 14 Cambridge Center, Building 6, Cambridge, MA
Panelists: Dr. Joanna Horobin, Chief Medical Officer, Verastem, Inc., Dr. Rosana Kapeller, Chief Scientific Officer, Nimbus Discovery, Daphne Zohar, Chief Executive Officer, Pure Tech Ventures
Moderator: Karen Weintraub, health and science journalist, author and former Boston Globe editor.
Sponsor: Northeastern's Alumni Association

The Next 25 Years of Boston Biotech
Date: Tuesday, October 29, 2013 (7:45 - 9:15 a.m.)
Location: Ritz Carlton Hotel, Boston, MA
Panelists: Robert Forrester, President/CEO, Verastem, Inc., Dr. Michelle Dipp, CEO & Co-founder, OvaScience, Katrine Bosley, Entrepreneur-in-Residence, Broad Institute of MIT & Harvard
Moderator: Rob Weisman, Reporter, The Boston Globe
Sponsor: Boston Chamber of Commerce

2013 Chabner Colloquium, Collaboration in Cancer Drug Trials; Stem Cells and Circulating Tumor Cells
Date: Tuesday, October 29, 2013 (10:15 - 11:00 a.m.)
Location: Starr Center, Schepens Eye Institute, Boston, MA
Panelists: Dr.Jonathan Pachter, Head of Research, Verastem, Inc.
Moderator: Dr. David Fisher, Mass General Hospital
Sponsor: Society for Translational Oncology and the Massachusetts General Hospital

About Verastem, Inc.
Verastem, Inc. (NAS: VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit

Forward-looking statements:
Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Verastem, Inc.
Brian Sullivan, 617-252-9314

KEYWORDS:   United States  North America  Massachusetts


The article Verastem Executives Featured at Boston-Area Biotechnology Events originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.